Factor XIII in severe sepsis and septic shock

Thrombosis Research

Volumn 119, Issue 3, 2007, Pages 311-318

  Zeerleder, Sacha ^a,b   Schroeder, Verena ^b   Lämmle, Bernhard ^b   Wuillemin, Walter A ^c   Hack, C Erik ^a,d   Kohler, Hans Peter ^b  

^a SANQUIN RESEARCH   (Netherlands)

^b UNIVERSITY OF BERN   (Switzerland)

^c LUZERNER KANTONSSPITAL   (Switzerland)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

DIC; FXIII; MODS; Sepsis; Transglutaminase

Indexed keywords

FACTOR XIIIA; FEMALE; FIBRINOLYSIS; HUMANS; MALE; MULTIPLE ORGAN FAILURE; SHOCK, SEPTIC; SURVIVAL RATE;

EID: 33845571245     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.02.003     Document Type: Article

References (29)

1. Rangel-Frausto M.S., Pittet D., Costigan M., Hwang T., Davis C.S., and Wenzel R.P. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273 (1995) 117-123
2. Bone R.C. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 24 (1996) 163-172
3. Zeerleder S., Hack C.E., and Wuillemin W.A. Disseminated intravascular coagulation in sepsis. Chest 128 (2005) 2864-2875
4. ten Cate H., Timmerman J.J., and Levi M. The pathophysiology of disseminated intravascular coagulation. Thromb Haemost 82 (1999) 713-717
5. Lorand L. Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann N Y Acad Sci 936 (2001) 291-311
6. Anwar R., and Miloszewski K.J. Factor XIII deficiency. Br J Haematol 107 (1999) 468-484
7. Ichinose A., and Aoki N. Reversible cross-linking of alpha 2-plasmin inhibitor to fibrinogen by fibrin-stabilizing factor. Biochim Biophys Acta 706 (1982) 158-164
8. Valnickova Z., and Enghild J.J. Human procarboxypeptidase U, or thrombin-activatable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin. J Biol Chem 273 (1998) 27220-27224
9. Senaldi G., and Piguet P.F. Mortality and platelet depletion occur independently of fibrinogen consumption in murine models of tumour necrosis factor-mediated systemic inflammatory responses. Cytokine 10 (1998) 382-389
10. Uchino R., Cardinali M., and Chung S. Regulation of extravascular fibrinolysis. Fibrinolysis 5 (1991) 93-98
11. Lee S.Y., Chang S.K., Lee I.H., Kim Y.M., and Chung S.I. Depletion of plasma factor XIII prevents disseminated intravascular coagulation-induced organ damage. Thromb Haemost 85 (2001) 464-469
12. Egbring R., Schmidt W., Fuchs G., and Havemann K. Demonstration of granulocytic proteases in plasma of patients with acute leukemia and septicemia with coagulation defects. Blood 49 (1977) 219-231
13. Seitz R., Wolf M., Egbring R., Radtke K.P., Liesenfeld A., Pittner P., et al. Participation and interactions of neutrophil elastase in haemostatic disorders of patients with severe infections. Eur J Haematol 38 (1987) 231-240
14. Tanaka H., Sugimoto H., Yoshioka T., and Sugimoto T. Role of granulocyte elastase in tissue injury in patients with septic shock complicated by multiple-organ failure. Ann Surg 213 (1991) 81-85
15. Holst F.G., Hemmer C.J., Foth C., Seitz R., Egbring R., and Dietrich M. Low levels of fibrin-stabilizing factor (factor XIII) in human Plasmodium falciparum malaria: correlation with clinical severity. Am J Trop Med Hyg 60 (1999) 99-104
16. Bone R.C., Balk R.A., Cerra F.B., Dellinger R.P., Fein A.M., Knaus W.A., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101 (1992) 1644-1655
17. LeGall J.R., Klar J., Lemeshow S., Saulnier F., Alberti C., Artigas A., et al. The logistic organ dysfunction system. A new way to assess organ dysfunction in the Intensive Care Unit. JAMA 276 (1996) 802-810
18. Vincent J.L., Moreno R., Takala J., Willatts S., De Mendonça A., Bruining H., et al. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. Intensive Care Med 22 (1996) 707-710
19. Caliezi C., Zeerleder S., Redondo M., Regli B., Rothen H.U., Zürcher-Zenklusen R., et al. C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit Care Med 30 (2002) 1722-1728
20. Ariens R.A., Kohler H.P., Mansfield M.W., and Grant P.J. Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals. Relation to sex, age, smoking, and hypertension. Arterioscler Thromb Vasc Biol 19 (1999) 2012-2016
21. Bland J.M., and Altman D.G. Multiple significance tests: the Bonferroni method. BMJ 310 (1995) 170
22. Kucher N., Schroeder V., and Kohler H.P. Role of blood coagulation factor XIII in patients with acute pulmonary embolism. Correlation of factor XIII antigen levels with pulmonary occlusion rate, fibrinogen, D-dimer, and clot firmness. Thromb Haemost 90 (2003) 434-438
23. D'Argenio G., Grossman A., Cosenza V., Valle N.D., Mazzacca G., and Bishop P.D. Recombinant factor XIII improves established experimental colitis in rats. Dig Dis Sci 45 (2000) 987-997
24. Seitz R., Leugner F., Katschinski M., Immel A., Kraus M., Egbring R., et al. Ulcerative colitis and Crohn's disease: factor XIII, inflammation and haemostasis. Digestion 55 (1994) 361-367
25. Born P., Lippl F., Ulm K., Gerein P., Lersch C., Eckel F., et al. Reduced levels of coagulation factor XIII in patients with advanced tumor disease. Hepatogastroenterology 47 (2000) 194-198
26. Caliezi C., Wuillemin W.A., Zeerleder S., Redondo M., Eisele B., and Hack C.E. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 52 (2000) 91-112
27. Kangsadalampai S. Board PG. The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood 92 (1998) 2766-2770
28. Wilmer M., Rudin K., Kolde H., Poetzsch B., Lenz W., Moessmer G., et al. Evaluation of a sensitive colorimetric FXIII incorporation assay. Effects of FXIII Val34Leu, plasma fibrinogen concentration and congenital FXIII deficiency. Thromb Res 102 (2001) 81-91
29. Siebenlist K.R., Meh D.A., and Mosesson M.W. Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin. Thromb Haemost 86 (2001) 1221-1228